Antibodies against GPR64 and uses thereof

Details Antibodies against GPR64 and uses thereof Antibodies against GPR64 and uses thereof

2007-09-07

2009-06-16

Rawlings, Stephen L (Department: 1643)

Chemistry: molecular biology and microbiology

Animal cell, per se ; composition thereof; process of...

Animal cell, per se, expressing immunoglobulin, antibody, or...

C530S387100, C530S387300, C530S387900, C530S388800, C530S391300, C530S391700

Reexamination Certificate

active

07547544

ABSTRACT:
GPR64 antibody compositions are provided. These antibodies may be used for diagnosis or treatment of cancer, especially ovarian cancer, Ewing's sarcoma, uterine cancer, and other GPR64 expressing tumor types.

REFERENCES:
patent: 6183968 (2001-02-01), Bandman
patent: 2002/0142951 (2002-10-01), Webster
patent: 2004/0005563 (2004-01-01), Mack
patent: 19617940 (1997-10-01), None
patent: 0805204 (1997-11-01), None
patent: 1033401 (2000-09-01), None
patent: 9845436 (1998-10-01), None
patent: 0034473 (2000-06-01), None
patent: 0056881 (2000-09-01), None
patent: 0154477 (2001-08-01), None
patent: 0170979 (2001-09-01), None
patent: 0210449 (2002-02-01), None
patent: 0261087 (2002-08-01), None
patent: 0279406 (2002-10-01), None
patent: 0283856 (2002-10-01), None
patent: 02101357 (2002-12-01), None
patent: 02102235 (2002-12-01), None
patent: WO02102235 (2002-12-01), None
patent: 03038129 (2003-05-01), None
patent: 03051925 (2003-06-01), None
patent: 03071272 (2003-08-01), None
patent: 2004037860 (2004-05-01), None
Osterhoff et al., “Cloning of a human epididymis-specific mRNA, HE6, encoding a novel member of the seven transmembrane-domain receptor superfamily,” DNA and Cell Biology, 16:379-389 (1997).
Obermann et al., “HE6, a two-subunit heptahelical receptor associated with apical membranes of efficient epididymal duct epithelia,” Molec. Reprod. & Develop. 64:13-26 (2003).
Gilewski et al., “Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21,” Clin. Cancer Res. 6:1693-1701 (2000).
Scholl et al., “Recombinant vaccinia virus encoding human MUC1 and IL2 as immunotherapy in patients with breast cancer,” J. Immunother. 23:570-580 (2000).
Bon et al., “Clinical and technical evaluation of ACS BR serum assay of MUC1 gene-derived glycoprotein in breast cancer, and comparison with CA 15-3 assays,” Clin. Chem. 43:585-593 (1997).
Fitzgibbons et al., “Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999,” Arch. Pathol. Lab. Med. 124:966-978 (2000).
Hamilton and Piccart, “The contribution of molecular markers to the prediction of response in the treatment of breast cancer: a review of the literature on HER-2, p53 and BCL-2,” Ann. Oncol. 11:647-663 (2000).
Robson, “Are BRCA1 and BRCA2-associated breast cancers different? Prognosis of BRCA-1 associated breast cancer,” J. Clin. Oncol. 18(21 Suppl):113S-118S (2000).
Fredriksson R., et al., “Novel human G protein-coupled receptors with long N-terminal containing GPS domains and Ser/Thr-rich regions,” FEBs Letters 531:407-414 (2002).
Genbank accession CAA57479 (1996).
Genbank accession X81892 (1996).
Doronina et al., “Development of potent monoclonal antibody auristatin conjugates for cancer therapy,” Nature Biotech, 21(7):778-784 (Jul. 2003).
Delphion Record for EP0805204B1 (Nov. 2006).
Toki et al., “Cures and regressions of established tumor xenografts with monoclonal antibody auristatin E conjugates,” ACS National Meeting, No. 223rd, p. 1, abstract (Apr. 7, 2002).

Affiliated with

Also associated with

Rating

Antibodies against GPR64 and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antibodies against GPR64 and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies against GPR64 and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4112737